Pazopanib hydrochloride

Pazopanib

Pazopanib: A Key Player in Advanced Renal Cell Carcinoma Treatment[edit | edit source]

Pazopanib is a potent anticancer agent extensively used in the management of advanced renal cell carcinoma (RCC), the predominant type of kidney cancer. Beyond RCC, pazopanib's spectrum extends to the treatment of advanced soft tissue sarcoma and its potential role in managing other malignancies is under exploration.

Clinical Applications[edit | edit source]

Primary Use: Pazopanib stands as a frontline therapeutic option for patients diagnosed with advanced renal cell carcinoma, the most frequent variant of kidney cancer^[1].

Secondary Indications: Besides RCC, pazopanib has demonstrated efficacy in treating advanced soft tissue sarcoma, especially in patients who have been previously treated with other anticancer drugs^[2].

Research Frontiers: Current research endeavors are evaluating the potential benefits of pazopanib in treating other malignancies.

Mechanism of Action[edit | edit source]

Pazopanib, primarily known as pazopanib hydrochloride, functions by thwarting the formation of new blood vessels, a process essential for tumor progression and growth. By inhibiting this angiogenic process, the drug impedes tumor expansion and potentially leads to its regression^[3].

Classification[edit | edit source]

Type: Pazopanib is classified as a protein tyrosine kinase inhibitor. This class of drugs is known to block specific enzymes which contribute to cancer cell growth and proliferation.
Function: Furthermore, given its action against blood vessel formation, it is also recognized as an antiangiogenesis agent, making it instrumental in restricting the vascular supply to tumors.

Other Names[edit | edit source]

In the pharmaceutical world, Pazopanib is also referred to by other designations:

GW786034
Trade name: Votrient

Conclusion[edit | edit source]

Pazopanib, with its distinctive mode of action and proven efficacy in renal cell carcinoma and soft tissue sarcoma, has made a significant impact on the oncology therapeutic landscape. The drug's promise in curtailing tumor growth by targeting blood vessel formation offers a ray of hope to patients and warrants further research into its potential applications in other cancer types.

References[edit | edit source]

↑ Escudier, B., Porta, C., Schmidinger, M., Algaba, F., Patard, J. J., Khoo, V., ... & Eisen, T. (2014). Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 25(suppl_3), iii49-iii56.
↑ van der Graaf, W. T., Blay, J. Y., Chawla, S. P., Kim, D. W., Bui-Nguyen, B., Casali, P. G., ... & Hohenberger, P. (2012). Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. The Lancet, 379(9829), 1879-1886.
↑ Kumar, R., Knick, V. B., Rudolph, S. K., Johnson, J. H., Crosby, R. M., Crouthamel, M. C., ... & Mallamo, J. P. (2007). Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Molecular cancer therapeutics, 6(7), 2012-2021.

Pazopanib hydrochloride Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski

Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD

Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD

WikiMD is not a substitute for professional medical advice. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.

[1] Escudier, B., Porta, C., Schmidinger, M., Algaba, F., Patard, J. J., Khoo, V., ... & Eisen, T. (2014). Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 25(suppl_3), iii49-iii56.

[2] van der Graaf, W. T., Blay, J. Y., Chawla, S. P., Kim, D. W., Bui-Nguyen, B., Casali, P. G., ... & Hohenberger, P. (2012). Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. The Lancet, 379(9829), 1879-1886.

[3] Kumar, R., Knick, V. B., Rudolph, S. K., Johnson, J. H., Crosby, R. M., Crouthamel, M. C., ... & Mallamo, J. P. (2007). Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Molecular cancer therapeutics, 6(7), 2012-2021.

[1]

[2]

[3]